Perrigo (PRGO) Expected to Announce Quarterly Earnings on Thursday

Perrigo (NYSE:PRGO) is anticipated to post its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Perrigo to post earnings of $0.80 per share and revenue of $1.0921 billion for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:30 AM ET.

Perrigo Stock Performance

NYSE:PRGO opened at $14.61 on Thursday. The company has a quick ratio of 1.44, a current ratio of 2.51 and a debt-to-equity ratio of 0.81. The firm has a 50-day moving average price of $14.23 and a 200 day moving average price of $17.92. The firm has a market capitalization of $2.01 billion, a PE ratio of -38.43, a price-to-earnings-growth ratio of 1.30 and a beta of 0.39. Perrigo has a 12-month low of $12.17 and a 12-month high of $30.93.

Wall Street Analysts Forecast Growth

Several research firms recently commented on PRGO. JPMorgan Chase & Co. cut their target price on Perrigo from $20.00 to $18.00 and set a “neutral” rating for the company in a research report on Monday, December 15th. Argus raised Perrigo to a “hold” rating in a report on Wednesday, January 14th. Canaccord Genuity Group reduced their target price on shares of Perrigo from $40.00 to $20.00 and set a “buy” rating on the stock in a research note on Thursday, November 6th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Perrigo in a research report on Monday, December 22nd. Finally, Wall Street Zen lowered shares of Perrigo from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. One analyst has rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $20.33.

Institutional Trading of Perrigo

Hedge funds have recently modified their holdings of the stock. Fuller & Thaler Asset Management Inc. increased its holdings in shares of Perrigo by 291.9% in the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 7,824,759 shares of the company’s stock valued at $108,921,000 after purchasing an additional 5,828,076 shares in the last quarter. ION Fund Management Ltd bought a new position in Perrigo in the 4th quarter valued at $24,499,000. Ion Asset Management Ltd. increased its stake in shares of Perrigo by 34.7% in the 2nd quarter. Ion Asset Management Ltd. now owns 3,817,621 shares of the company’s stock valued at $102,007,000 after buying an additional 983,727 shares during the period. Bridgeway Capital Management LLC bought a new stake in shares of Perrigo during the fourth quarter worth $9,165,000. Finally, Price T Rowe Associates Inc. MD lifted its stake in shares of Perrigo by 3.9% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 17,574,227 shares of the company’s stock valued at $244,634,000 after acquiring an additional 653,925 shares during the period. 95.91% of the stock is owned by institutional investors.

Perrigo Company Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.